Profile data is unavailable for this security.
About the company
Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)6.56bn
- Net income in HKD932.51m
- Incorporated2010
- Employees3.54k
- LocationShanghai Henlius Biotech Inc11/F, B8 Building, No. 188 Yizhou Road,SHANGHAI 200233ChinaCHN
- Fax+86 2 134611802
- Websitehttps://www.henlius.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consun Pharmaceutical Group Ltd | 3.70bn | 1.14bn | 16.29bn | 3.07k | 14.56 | 3.35 | 13.38 | 4.41 | 1.33 | 1.33 | 4.31 | 5.77 | 0.5642 | 2.35 | 12.33 | 1,168,208.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| Zai Lab Ltd | 3.45bn | -1.62bn | 17.10bn | 1.87k | -- | 2.82 | -- | 4.96 | -1.52 | -1.52 | 3.21 | 5.37 | 0.4119 | 3.19 | 6.53 | -- | -19.29 | -33.80 | -27.61 | -39.12 | 61.52 | 64.07 | -46.83 | -186.77 | 2.68 | -- | 0.2108 | -- | 49.59 | 98.38 | 23.17 | -- | 32.19 | -- |
| Ascletis Pharma Inc | 2.67m | -292.51m | 17.61bn | 208.00 | -- | 7.57 | -- | 6,586.55 | -0.299 | -0.299 | 0.0027 | 2.19 | 0.0011 | 0.2668 | 11.59 | 11,577.28 | -12.10 | -8.46 | -12.73 | -8.80 | 36.21 | 7.91 | -10,937.78 | -522.12 | 14.53 | -- | 0.0023 | -- | -97.73 | -62.52 | -107.95 | -- | -40.26 | -- |
| Vigonvita Life Sciences Co Ltd | -100.00bn | -100.00bn | 20.11bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -94.07 | -- | -1,848.73 | -- | -- | -- |
| HUTCHMED (China) Ltd | 4.71bn | 3.65bn | 20.31bn | 1.78k | 5.57 | 2.11 | 5.42 | 4.32 | 4.18 | 4.18 | 5.39 | 11.01 | 0.3966 | 7.09 | 3.86 | 2,598,625.00 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Ab&B Bio Tech Co Ltd JS | 366.26m | -253.89m | 22.39bn | 583.00 | -- | 587.93 | -- | 61.12 | -0.6453 | -0.6453 | 0.9309 | 0.0968 | -- | -- | -- | -- | -- | -- | -- | -- | 67.29 | -- | -69.32 | -- | 0.3162 | -9.49 | 0.9646 | -- | 397.65 | -- | 39.09 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 6.56bn | 932.51m | 24.40bn | 3.54k | 41.09 | 9.94 | 17.29 | 3.72 | 1.72 | 1.72 | 12.07 | 7.09 | 0.5386 | 1.73 | 5.86 | 1,866,014.00 | 7.66 | -3.21 | 13.85 | -5.76 | 75.77 | 72.50 | 14.22 | -7.87 | 0.5046 | 10.47 | 0.5185 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.95bn | 3.46bn | 24.84bn | 17.40k | 6.60 | 1.30 | 5.96 | 1.56 | 1.91 | 1.91 | 8.78 | 9.69 | 0.5397 | 2.89 | 5.97 | 938,419.90 | 11.71 | 9.37 | 17.46 | 14.54 | 47.24 | 44.33 | 21.70 | 15.06 | 1.60 | -- | 0.2472 | 26.01 | 0.1387 | 10.39 | -1.54 | 32.89 | 37.25 | 45.96 |
| Sunshine Lake Pharma Co Ltd | 3.82bn | -447.93m | 25.20bn | 6.53k | -- | 56.99 | 21,090.14 | 6.60 | -0.7768 | -0.7768 | 6.62 | 0.7674 | -- | -- | -- | 582,850.30 | -- | -- | -- | -- | 73.62 | -- | -12.86 | -- | 0.7739 | -0.7591 | 0.5111 | -- | -37.06 | -- | -212.17 | -- | -- | -- |
| PegBio Co Ltd | -100.00bn | -100.00bn | 26.05bn | 58.00 | -- | 89.02 | -- | -- | -- | -- | -- | 0.7481 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.07 | -- | 0.2439 | -- | -- | -- | -1.49 | -- | -- | -- |
| Grand Pharmaceutical Group Ltd | 11.70bn | 2.08bn | 26.80bn | 12.44k | 12.70 | 1.54 | 10.34 | 2.29 | 0.5943 | 0.5943 | 3.35 | 4.90 | 0.4557 | 3.66 | 3.88 | 976,472.80 | 7.99 | 10.40 | 10.81 | 14.24 | 57.64 | 61.04 | 17.53 | 22.80 | 0.9872 | -- | 0.2107 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
| China Resources Pharmaceutical Group Ltd | 295.20bn | 3.19bn | 28.84bn | 86.00k | 9.03 | 0.5101 | 2.21 | 0.0977 | 0.5084 | 0.5084 | 46.99 | 9.00 | 0.9434 | 5.57 | 2.41 | 4,060,518.00 | 2.86 | 3.14 | 10.28 | 11.78 | 15.81 | 15.59 | 3.03 | 3.02 | 1.12 | 11.26 | 0.4248 | 22.38 | 5.30 | 7.41 | -13.06 | 2.95 | 12.42 | 7.30 |
| Duality Biotherapeutics Inc | 2.46bn | -3.20bn | 30.92bn | 191.00 | -- | 9.16 | -- | 12.59 | -36.95 | -36.95 | 28.68 | 37.43 | -- | -- | -- | 14,442,920.00 | -- | -- | -- | -- | 37.13 | -- | -130.43 | -- | -- | -- | 0.0228 | -- | 8.66 | -- | -193.82 | -- | -- | -- |
| Simcere Pharmaceutical Group Ltd | 8.04bn | 995.72m | 32.71bn | 6.82k | 31.13 | 3.81 | 23.46 | 4.07 | 0.4048 | 0.4048 | 3.26 | 3.31 | 0.5845 | 2.20 | 2.81 | 1,221,077.00 | 7.24 | 8.74 | 9.93 | 12.42 | 81.00 | 78.53 | 12.39 | 15.60 | 1.57 | 4.72 | 0.1453 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
Data as of Feb 16 2026. Currency figures normalised to Shanghai Henlius Biotech Inc's reporting currency: Hong Kong Dollar HKD
33.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Boyu Capital Investment Management Co. Ltd.as of 04 Feb 2026 | 12.15m | 7.43% |
| GIC Pte Ltd. (Investment Management)as of 04 Feb 2026 | 11.89m | 7.28% |
| Taikang Asset Management (Hong Kong) Co., Ltd.as of 04 Feb 2026 | 10.32m | 6.32% |
| UBS Asset Management Switzerland AGas of 30 Jan 2026 | 8.05m | 4.92% |
| Point72 Asset Management LPas of 05 Sep 2025 | 7.60m | 4.65% |
| Fullgoal Asset Management (HK) Ltd.as of 30 Jun 2025 | 2.67m | 1.63% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 543.90k | 0.33% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 361.10k | 0.22% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 353.10k | 0.22% |
| UBS Switzerland AG (Investment Management)as of 30 Jan 2026 | 253.70k | 0.16% |
More ▼
Data from 30 Sep 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
